High dose of antiviral drug, Favipiravir extended the survival in non-human primates infected with Ebola virus. In the past, there was no effective treatment reported for Ebola virus disease (EVD) and as per the initial studies Favipiravir presented a good tolerance profile in patients infected with ebola but could not result in strong antiviral efficacy. A new study demonstrates that high doses of antiviral drug, inhibited the viral replication in a dose dependent method showing maximum therapeutic effect at a dose of 180mg/kg.
In order to maintain Public health management of future outbreaks, Favipiravir efficacy was analysed on non-human primates. These successful results along with the previous data collected on tolerance and pharmacokinetics in both non-humans and humans plays a potential role for high doses of favipiravir for future human interventions. Do you agree with this…
